| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ceo/ CFO | CEO, CFO | CEO and CFO
1 company
David Emerson Jorden is Ceo/ CFO at AURX. David Emerson Jorden's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.6M at current prices.
Net of sales, the AURX filings show accumulation of 22,500 shares.
David Emerson Jorden has 15 Form 4 filings on record from July 2015 to August 2026, all as Ceo/ CFO at Nuo Therapeutics (AURX), 2015–2026.
The 34 reported transactions were 10 open-market sales, 7 option or other derivative awards, 4 stock awards and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $192K and 2 sales worth about $544K.
The largest open-market purchase was 137,500 shares of AURX at an average $1.00 on May 5, 2016, about $138K.
The largest open-market sale was 200,000 shares of AURX at an average $1.50 on November 28, 2025, about $300K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | AURX Nuo Therapeutics, Inc. | Ceo/ CFO | Sell | 200,000 | $1.50 | $300,000.00 | -9.3% | |
| Nov 9, 2022 | AURX Nuo Therapeutics, Inc. | Ceo/ CFO | Sell | 162,500 | $1.50 | $243,750.00 | -7.6% | |
| Aug 10, 2017 | AURX Nuo Therapeutics, Inc. | CEO, CFO | Buy | 247,500 | $0.22 | $54,994.50 | +79.9% | |
| May 5, 2016 | AURX Nuo Therapeutics, Inc. | CEO and CFO | Buy | 137,500 | $1.00 | $137,500.00 | New |